HROW
Market read
No new filing conclusion is available. 0 of 16 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Invalidation: The isolated read changes if HROW's group or a disclosed connection begins moving with it.
Research brief
No new filing conclusion is available. 0 of 16 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“The following presents our research and development expenses for the three months ended March 31, 2026 and 2025: Three Months Ended March 31, 2026 2025 $ Variance Research and development $ 5,895,000 $ 3,026,000 $ 2,869,000 The increase in R&D expenses of $2,…”10-Q · May 11, 2026 ↗
“ImprimisRx For the Years Ended December 31, $ 2025 2024 Variance Cost of sales $ 30,704,000 $ 27,578,000 $ 3,126,000 The increase in ImprimisRx costs of sales between the years ended December 31, 2025 and 2024 was primarily attributable to product mix that in…”10-K · Mar 2, 2026 ↗
“Cash provided by financing activities during the year ended December 31, 2024 was primarily due to additional borrowings under our long-term debt facility with Oaktree of $29,780,000, net of issuance costs, and proceeds from the exercise of stock options, off…”10-K · Mar 2, 2026 ↗
“As a result of the cyberattack, its orders and sales for certain products were negatively affected.”10-K · Mar 2, 2026 ↗
Valuation discipline
Price/sales 4.9× · EV/sales 5.6×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for HROW. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for HROW. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
HROW is currently a Leader in the organic co-movement group Mining and Tech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for HROW; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.